Versartis Inc. (VSAR) Stock Price Down 1.7%
Shares of Versartis Inc. (NASDAQ:VSAR) fell 1.7% during mid-day trading on Friday . The stock traded as low as $11.31 and last traded at $11.56, with a volume of 125,835 shares changing hands. The stock had previously closed at $11.76.
Several brokerages have issued reports on VSAR. Credit Suisse Group AG reaffirmed a “sell” rating and set a $9.00 target price on shares of Versartis in a research report on Friday. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a report on Wednesday, June 29th. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a report on Tuesday, May 10th. Morgan Stanley reiterated a “hold” rating on shares of Versartis in a report on Saturday, April 30th. Finally, Northland Securities began coverage on Versartis in a report on Thursday, April 7th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $16.60.
The stock’s market capitalization is $338.42 million. The stock has a 50-day moving average price of $10.87 and a 200 day moving average price of $9.34.
Versartis (NASDAQ:VSAR) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. Equities research analysts forecast that Versartis Inc. will post ($3.29) earnings per share for the current fiscal year.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.